ST中珠(600568) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥122,493,820.06, representing a year-on-year increase of 31.17%[5] - The net profit attributable to shareholders was a loss of ¥4,107,942.56, an increase in loss of 83.41% compared to the same period last year[5] - Basic earnings per share were -¥0.0021, with a year-on-year increase in loss of 83.06%[6] - Total operating revenue for Q1 2022 was CNY 122,493,820.06, an increase of 31.2% compared to CNY 93,388,534.23 in Q1 2021[20] - Total operating costs for Q1 2022 were CNY 126,995,078.54, up 10.9% from CNY 114,527,575.61 in Q1 2021[20] - Net profit for Q1 2022 was CNY 1,621,721.13, a significant recovery from a net loss of CNY 26,438,456.07 in Q1 2021[21] - The company reported a comprehensive income total of CNY 1,622,794.27 for Q1 2022, compared to a comprehensive loss of CNY 26,545,729.18 in Q1 2021[22] - Basic and diluted earnings per share for Q1 2022 were both CNY -0.0021, improving from CNY -0.0124 in Q1 2021[22] Cash Flow - The net cash flow from operating activities was a negative ¥32,622,357.77, reflecting a significant decline of 6,011.91%[5] - Cash flow from operating activities showed a net outflow of CNY -32,622,357.77 in Q1 2022, compared to a smaller outflow of CNY -533,750.57 in Q1 2021[25] - Cash inflow from investment activities was CNY 102,763,906.22 in Q1 2022, a decrease from CNY 122,444.09 in Q1 2021[25] - The company recorded a net cash inflow from investment activities of CNY 89,680,865.10 in Q1 2022, contrasting with a net outflow of CNY -123,595,874.39 in Q1 2021[25] - The net cash flow from financing activities was -$21,721,780.07, a decrease of $1,355,953.02 compared to the previous period[26] - The total cash and cash equivalents at the end of the period amounted to $562,683,660.16, showing a decrease from $694,509,394.33 at the beginning of the period[26] - The net increase in cash and cash equivalents was $35,336,727.26, compared to a decrease of $125,485,577.98 in the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,402,604,124.20, a decrease of 1.24% from the end of the previous year[6] - As of March 31, 2022, the total assets amounted to RMB 4,402,604,124.20, a decrease from RMB 4,457,864,645.56 at the end of 2021, reflecting a decline of approximately 1.24%[18] - Total current liabilities decreased to RMB 349,276,322.56 from RMB 402,659,497.81, showing a reduction of around 13.3%[19] - The total liabilities decreased to RMB 672,353,538.43 from RMB 729,236,854.06, reflecting a decline of about 7.8%[19] - The company's inventory stood at RMB 636,797,918.70, slightly down from RMB 641,676,842.66, indicating a decrease of approximately 0.77%[18] - The total equity attributable to shareholders was RMB 3,593,336,128.96, a slight decrease from RMB 3,597,442,998.38, representing a decline of about 0.11%[19] - The company reported a net loss of RMB 1,505,935,246.61 in retained earnings, worsening from a loss of RMB 1,501,827,304.05[19] - The long-term investments remained stable at RMB 608,370,985.34, with a minor decrease from RMB 609,512,710.44[18] Research and Development - The company's research and development expenses decreased by 55.66% due to reduced investment in the pharmaceutical sector[11] - Research and development expenses decreased to CNY 3,727,371.97 in Q1 2022 from CNY 8,405,433.57 in Q1 2021, indicating a strategic shift in R&D investment[20] Other Notable Points - The company received a significant tax refund, resulting in a 100% increase in cash received from tax refunds[11] - The company reported a 46.45% increase in accounts receivable due to new medical insurance settlement receivables[10] - The company’s short-term borrowings increased by 50.10% due to new credit borrowings from subsidiaries[10] - The company’s cash received from the disposal of fixed assets increased by 303.09% compared to the previous period[11] - The company has not disclosed any significant new product developments or market expansion strategies during this reporting period[16]